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Marco Mucerino, MD, Vito Antonio Mannacio, MD, PhD, and Carlo Vosa, MD, PhD
Department of Clinical Medicine and Cardiovascular Sciences, Division of Adult and Pediatric Cardiac Surgery, University of
Naples Federico II, Naples, ItalyBackground. We conducted a retrospective study of
cyanotic and acyanotic patients undergoing cardiopul-
monary bypass to determine the effect of tranexamic acid
on blood loss and blood products administered during
the operation in pediatric cardiac surgery.
Methods. From January 2008 to December 2011, during
2 different periods, a total of 231 pediatric patients
undergoing cardiac surgery with cardiopulmonary by-
pass (123 cyanotic, 108 acyanotic) were included in this
study. A total of 104 patients were in the antifibrinolytic
group and exclusively treated with tranexamic acid that
was given as a bolus of 20 mg/kg1 after anesthetic
induction and 20 mg/kg1 after protamine. The other 127
patients were in the control group. We analyzed intraop-
erative and postoperative outcomes of tranexamic acid
administration.
Results. There were no differences in mortality oroperative time, but blood loss in 48 hours was greater in
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 byats.ctsnetjournals.orgDownloaded from the control group (p  0.0012). A significant difference
was found in the amount of intraoperative erythrocyte
concentrate transfused (140  55 vs 170  78 mL, p 
0.0011) but not in number. The number and amount of
erythrocyte concentrate transfused in the first 48 postop-
erative hours were also greater in the control group (45 vs
77 patients, p  0.012; 100  40 vs 120  55 mL, p 
0.0022). There were not many differences in the effect of
tranexamic acid between the cyanotic and acyanotic
subgroup.
Conclusions. This retrospective study provides evi-
dence that tranexamic acid may be used in the field of
congenital cardiac surgery effectively.
(Ann Thorac Surg 2012;94:1302–6)
© 2012 by The Society of Thoracic SurgeonsOpen heart surgery in children with congenital heartdisease often results in coagulation disturbances
that may lead to intraoperative and postoperative loss of
blood [1]. As transfusion of homologous blood compo-
nents is associated with infectious and immunologic risks
as well as increased mortality, blood-saving strategies are
essential to reduce the amount of homologous blood
used.
The use of antifibrinolytic agents to reduce blood loss
after pediatric cardiac surgery has been described in
several studies [1–11]. Tranexamic acid (TXA), an analog
of the amino acid lysine, is an antifibrinolytic agent that
competes with plasminogen for binding sites on fibrin
and also prevents plasmin-induced platelet activation
[12]. Although the presence of cyanosis would be associ-
ated with more bleeding episodes due to collateral vessel
formation and platelet dysfunction caused by erythrocy-
tosis [13], it is unclear whether there is a difference in the
effects of TXA in cyanotic and acyanotic patients. We
conducted a retrospective study of cyanotic and acya-
notic patients undergoing cardiopulmonary bypass to
determine the effect of TXA on blood loss and blood
Accepted for publication April 19, 2012.
Address correspondence to Dr Giordano, Via G. Filangieri 125/A, Cavaproducts administered during the operation in pediatric
cardiac surgery.
Material and Methods
Patient Selection
The data used in this retrospective study were collected
at our center during 2 different periods. Ethical commit-
tee approval was gained from the Ethics Committee of
the University of Naples Federico II. The Institutional
Review Board had approved the use of databases for
research. All participants were younger than 18 years of
age and each legal guardian had preliminarily granted
permission for the use of their medical records for
research purposes. Children younger than 18 years of age
who were scheduled to undergo elective cardiac surgery
with cardiopulmonary bypass (CPB) between January
2008 and December 2011 were considered potentially
eligible for inclusion in the study.
The control group included patients who underwent
surgery between January 2008 and December 2009. Dur-
ing this period no antifibrinolytic agent was used. The
tranexamic acid group was comprised of children oper-
ated between January 2010 and December 2011. From
then onward, all patients were exclusively treated with
0003-4975/$36.00
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Ctranexamic acid that was given as a bolus of 20 mg/kg1
of TXA after anesthetic induction and 20 mg/kg1 after
protamine, as advocated by Chauhan and colleagues [5].
Neonates of less than 1 month of age, on mechanical
ventilation preoperatively, and on inotropic support be-
fore surgery, were excluded from the study. Other exclu-
sion criteria were a preexisting coagulation disorder,
minimally invasive surgery, obvious kidney or liver dis-
ease, and known allergy to TXA. We included patients
with preoperative anticoagulation therapy, such as ad-
ministration of warfarin, aspirin, and ticlopidine. In our
basic strategy, patients are requested to cease all antico-
agulants 7 days before surgery [14].
Perioperative Management of Patients
All other parameters that may influence the periopera-
tive management, in particular anesthesia and CPB
course, were not modified during the 2 periods under
review. All patients were operated upon by a surgical
team of 3 surgeons. The following laboratory parameters
were measured preoperatively, immediately after sur-
gery, and 24 hours later: partial thromboplastin time
(PTT), Quick, fibrinogen, platelets account, and serum
creatinine. The transfusion amounts of erythrocyte con-
centrate, fresh frozen plasma, and platelets were deter-
mined for the operative period and the first 48 postoper-
ative hours. Blood loss through the drains was defined as
the amount of blood lost through the thoracic drains 48
hours after surgery. The anesthesiologists were respon-
sible for intraoperative fluid management. Left atrial
pressure or central venous pressure was maintained at 8
to 12 mm Hg to keep preload.
Postoperative care was undertaken by a team of inten-
sivists who were blinded to the study groups and who
managed bleeding and blood product administration
according to existing protocols. Packed red cells were
used for transfusion if the hemoglobin fell below 11 g/dL,
although a clear-cut trigger of transfusion was not de-
fined in this study. Fresh frozen plasma was used if the
hemoglobin was above 11 g/dL and the patients clotting
factors were considered based on the results of coagula-
tion tests. Platelet concentrates were used in a dose of 1
unit (50 mL) per 10 kg, and 5% albumin was used for
volume replacement if no active bleeding was present.
Aristotle score comprehensive [15] was used to compare
the complexity of procedures between the 2 groups.
Statistical Analysis
Continuous data are presented as mean  SD. We
compared clinical variables between the 2 groups by
means of the nonparametric Mann-Whitney U test (for
continuous variables) or the 2 and Fisher exact tests (for
categoric variables). A p value of less than 0.05 was
considered statistically significant. Data were analyzed
by means of Statistica 6.0 software (StatSoft, Inc, Tulsa,
OK).
 byats.ctsnetjournals.orgDownloaded from Results
Perioperative Parameters
In this study we included 231 patients; 104 in TXA group
and 127 in the control group. There was no difference
between the TXA group and control group (Table 1)
except for the preoperative values of fibrinogen; how-
ever, the levels of this variable were within normal range.
The intraoperative and postoperative parameters (Ta-
ble 2) were not different for mortality or operative time,
but the blood loss in 48 hours was greater in the control
group (187  85 vs 225  90 mL, respectively, p  0.0012).
No complications in the form of renal problems or
cerebral events were noted in any of the children studied.
There were only 2 patients requiring reexploration of the
chest for bleeding, both in the control group.
Required Blood Products
Blood products were required by 65 patients (63%) in the
TXA group and 91 patients (72%) in the control group
(p  0.18). Considering the intraoperative and postoper-
ative (48-hour) requirements for blood products (Table
3), no significant difference was found in the number and
amount of platelets concentrate or fresh frozen plasma
transfused. A significant difference was found in the
amount of intraoperative erythrocyte concentrate trans-
fused (140  55 [TXA group]) vs 170  78 mL [control
group], p  0.0011) but not in number (60 vs 84 patients,
p  0.23) and in the number and amount of erythrocyte
concentrate transfused in the first 48 postoperative hours
(45 vs 77 patients, p  0.012; 100  40 vs 120  55 mL, p 
0.0022).
Postoperative coagulation parameters were notable for
the increased PTT values in both groups, with greater
difference in the control group (45  21 vs 54  18, p 
Table 1. Demographic and Preoperative Data Between the
TXA and Control Groups
Patient Characteristics
TXA
Group
(n  104)
Control Group
(n  127) p Value
Age (months) 37.5  9.2 35.3  11.4 0.11
Gender (male) 61 (58.6%) 69 (54.3%) 0.59
Weight (Kg) 11.1  2.5 10.5  2.8 0.09
BSA (m2) 0.49  0.15 0.46  0.13 0.10
Repeat sternotomy 37 (35.4%) 38 (30.3%) 0.44
Aristotle score 8.6  2.3 9.1  2.7 0.13
Hemoglobin (g/dL) 12.9 0.7 13.1  1.3 0.16
Creatinine (mg/dL) 0.37 0.2 0.42  0.2 0.07
aPTT (seconds) 38.5 6.5 40.3  8.1 0.07
Quick (%) 89.4  4.4 90.5  5.2 0.09
Fibrinogen (mg/dL) 287 41 265  35 0.0001
ATIII (%) 95  11 93  12 0.19
Platelets (103/mL) 266  60 283  79 0.07
aPTT  activated partial thromboplastin time; ATIII  antithrombin
III; BSA  body surface area; Quick (%)  prothrombin activity
(normal value 70 to 130); TXA  tranexamic acid.0.0005) (Table 4). The activated partial thromboplastin
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still significantly higher 24 hours after intervention, as
compared with the TXA group (37  10 vs 41  12, p 
0.007).
Subgroup Analysis
The subgroup of children cyanotic and acyanotic was
analyzed separately (Table 5). There was just a signifi-
cantly higher amount (intraoperative) and number (post-
operative) of erythrocyte concentrate used in the control
cyanotic group (p  0.047 and p  0.03). Then, there was
a significantly higher intraoperative amount of platelets
concentrate transfused in the control acyanotic patients,
but the number of patients was very small.
Comment
Excessive bleeding leads to increases in morbidity and
mortality in adults [16] and children [17] after cardiac
surgery with cardiopulmonary bypass. Excessive bleed-
ing in children can be as much as 110 mL · kg1 · 24
hours1 [18], blood transfusion may become necessary,
and allogeneic blood transfusion may increase mortality
[19]. Although major causes of postoperative bleeding in
pediatric cardiac surgery are thrombocytopenia, platelet
dysfunction, and hemodilution, one possible cause is
Table 2. Intraoperative and Postoperative Parameters
Variable T
Mortality within the first 30 days
Total operation time (minutes)
CPB time (minutes)
Aortic clamp time (minutes)
CPB temperature (°C)
Early reoperation for bleeding
Intubation time (hours)
ICU stay (hours)
Total blood loss (in 48 hours) (mL)
Relative blood loss (in 48 hours) (mL/kg)
Creatinine (mg/dL)
Fluid balance (in 48 hours) (mL) 
CPB  cardiopulmonary bypass; ICU  intensive care unit; TXA
Table 3. Amounts of Blood Products Administered During an
Variable TX
Transfusion 6
Blood products intraoperative (mL)
Erythrocyte concentrate 140 
Platelet concentrate 40 
FFP 120 
Blood products within the first 48 hours (mL)
Erythrocyte concentrate 100 
Platelet concentrate 50 
FFP 90 FFP  fresh frozen plasma; TXA  tranexamic acid.
 byats.ctsnetjournals.orgDownloaded from increased fibrinolysis during CPB [20, 21], which occurs
in about 16% of patients [22]. Moreover, congenital heart
disease itself in pediatric patients has been shown to be
associated with fibrinolysis [22, 23].
We conducted a retrospective study to assess the
benefit of TXA in pediatric cardiac surgery in a single-
center population, with a good number of participants
(231 patients) in relation to the literature, in which
cyanotic (123) and acyanotic (108) patients were dis-
cretely balanced (1:13 ratio). Neonates of less than 1
month of age were excluded from this study because for
them coagulation disorders are known to be much stron-
ger than in other age groups [10].
In this study, TXA significantly reduced blood loss and
reduced intraoperative and postoperative amount and
number of erythrocyte concentrate transfused (only post-
operative), but it did not alter the amount of other blood
products administered. We found a few statistical differ-
ences in the effect of TXA treatment in cyanotic and
acyanotic patients. The results obtained in the literature
for postoperative blood loss and other outcomes are
generally heterogeneous and no clear results could be
interpreted.
All previous studies were, as ours, single-center stud-
ies. Of these earlier studies, 2 were double-blinded
roup Control Group p Value
3 0.59
 62 311  88 0.08
 33 100  39 0.14
 22 69  21 0.08
 2 30  2 0.06
2 0.3
 13 24  15 0.28
 34 81  41 0.32
 85 225  90 0.0012
 7.5 21  8.1 0.0019
 0.2 0.54  0.2 0.13
 170 320  190 0.14
nexamic acid.
48 Hours After the Operation
roup Control Group p Value
%) 91 (72%) 0.18
n  60) 170  78 (n  84) 0.0011 (0.23)
n  4) 50  10 (n  5) 0.19 (0.62)
n  57) 110  70 (n  65) 0.26 (0.67)
n  45) 120  55 (n  77) 0.0022 (0.012)
n  4) 50  20 (n  5) 1.0 (0.62)
n  55) 100  50 (n  74) 0.14 (0.49)XA G
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Cstudies [7, 9] that showed negative effects of TXA on both
bleeding and amount of transfusion products required.
The study by Bulutcu and colleagues [3], which in-
cluded 50 children and in which anesthesiologist and
perfusionist were not blinded to patients’ allocation,
showed that TXA was effective in terms of both blood loss
and transfusion. Three studies conducted by the same
group (Chauhan and colleagues [4–6]) showed TXA had
desirable effects. Nevertheless they included relatively
large numbers of patients while other studies had fewer
than 100 participants. The proportion of cyanotic patients
varied among these earlier studies. Three studies in-
cluded cyanotic and acyanotic patients with congenital
Table 4. Postoperative Coagulation Parameters
Variable
TXA
Group
Control
Group p Value
Immediately postoperative
aPTT (s) 45  21 54  18 0.0005
Quick (%) 57  13 55  10 0.18
Fibrinogen (mg/dL) 140 56 153  62 0.09
Platelets (103/mL) 130 39 120  44 0.07
24-hours postoperative
aPTT (s) 37  10 41  12 0.007
Quick (%) 70  15 68  13 0.27
Fibrinogen (mg/dL) 225 65 240  73 0.10
Platelets (103/mL) 165  42 155  55 0.12
aPTT activated partial thromboplastin time; Quick (%) prothrom-
bin activity (normal value 70 to 130); TXA  tranexamic acid.
Table 5. Difference Between TXA Group and Control Group
Variable
Cyanotic
TXA
(n  55)
Control
(n  68)
Age (months) 37  8.9 35.1  10.8
Weight (kg) 11.5  2.2 10.8  2.5
BSA 0.48  0.13 0.47  0.12
Aristotle score 8.9  2 9.5  2.2
BP intraoperative (mL)
EC 144  58 177  82
(n  34) (n  48)
PC 50 56.6  5.7
(n  2) (n  3)
FFP 113  70 107  65
(n  27) (n  37)
BP after 48 hours (mL)
EC 107  45 125  60
(n  21) (n  40)
PC 60 56  23
(n  2) (n  3)
FFP 95  60 110  55
(n  31) (n  35)BP  blood products; BSA: body surface area; EC  erythrocyte con
TXA  tranexamic acid.
 byats.ctsnetjournals.orgDownloaded from heart disease [7–9] but 2 of these failed to show any TXA
benefit [7, 9]. Moreover, 4 recent studies [3–6] that
included all cyanotic patients have shown TXA beneficial
effects. A recent randomized study [10] demonstrated the
reduction in blood loss in pediatric cardiac surgery with
no statistical difference on TXA effect in each cyanotic
and acyanotic subgroup [10].
There is a large variation (10 to 100 mg/kg, bolus or
continuous infusion) in the recommended dose in pedi-
atric cardiac surgery [3–11]. In our study we practiced a
bolus of 20 mg/kg1 of TXA after anesthetic induction
and 20 mg/kg1 after protamine, as advocated by Chau-
han and colleagues [5].
As the authors wrote, the variability in the dosage
schemes used in the different studies is striking.
Moreover, the choice of TXA dosage was empirical
based on its effects on blood loss and not on pharmaco-
kinetic data regarding the fibrinolytic inhibiting activity
of the drug. Data concerning the relationship between
the dose of TXA and the appearance of adverse effects are
not available in the literature, but we could suppose that
the risk of side effects could be dose dependent, and high
doses of TXA could probably increase the risk of adverse
effect. In fact, the children’s dose schemes are clearly
extrapolated from adult studies.
In our study we had no complications related to the
administration of TXA. In the pediatric population, side
effects related to TXA administration are not well estab-
lished. Most of the studies available have evaluated the
effect on bleeding and blood product requirements, but
none were designed to evaluate postoperative outcomes
anotic and Acyanotic Patients
Acyanotic
p Valuep Value
TXA
(n  49)
Control
(n  59)
0.29 37.3  9.4 35.5  11.5 0.38
0.10 11.1  2.4 10.5  2.3 0.18
0.65 0.48  0.16 0.47  0.13 0.72
0.06 8.1  1.8 8.5  2.9 0.40
0.047 135  50 160  70 0.12
(0.40) (n  26) (n  36) (0.52)
0.22 30 40 0.009
(0.80) (n  2) (n  2) (0.74)
0.72 125  80 120  78 0.81
(0.68) (n  30) (n  27) (0.15)
0.23 95  35 114  50 0.11
(0.03) (n  24) (n  37) (0.21)
0.35 40 40  14 1
(0.08) (n  2) (n  2) (0.74)
0.29 80  48 95  45 0.21
(0.71) (n  24) (n  39) (0.10)in Cycentrate; FFP  fresh frozen plasma; PC  platelet concentrate;
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studies [24, 25] reported side effects related to TXA
administration during pediatric cardiac surgery. They
found 9.6% renal injury, 1.8% renal failure, 3.5% seizure,
and 2.6% other neurologic events. According to their
results, more than 500 patients per group are needed to
evaluate side effects related to TXA administration.
Study Limitations
The retrospective design of this study naturally impedes
inference of possible causalities. An historical control
group is utilized but alterations and improvements in the
surgical procedures and perioperative environment be-
tween the 2 periods can obviously not be ruled out. We
also excluded the neonatal population. Accordingly, a
large, multicenter, randomized controlled trial with es-
tablished doses is warranted to validate the efficacy of
TXA in comparison with placebo or other antifibrinolytic
drugs.
Conclusions
In conclusion, the data in this retrospective study provide
further evidence that the TXA may be used as an antifi-
brinolytic substance in the field of congenital cardiac
surgery with positive effectiveness, but the results of this
study raise no consistent concerns regarding the safety.
There were not many differences in the effects of TXA
treatment in cyanotic and acyanotic patients.
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